ProKidney (NASDAQ:PROK) and Innate Pharma (NASDAQ:IPHA) Financial Survey

ProKidney (NASDAQ:PROK – Get Free Report) and Innate Pharma (NASDAQ:IPHA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Profitability

This table compares ProKidney and Innate Pharma’s net margins, return on equity and return on assets.

Insider and Institutional Ownership

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 41.5% of ProKidney shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ProKidney and Innate Pharma”s gross revenue, earnings per share and valuation.

Innate Pharma has higher revenue and earnings than ProKidney.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ProKidney and Innate Pharma, as provided by MarketBeat.com.

ProKidney currently has a consensus price target of $4.50, suggesting a potential upside of 128.43%. Innate Pharma has a consensus price target of $11.50, suggesting a potential upside of 480.81%. Given Innate Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe Innate Pharma is more favorable than ProKidney.

Risk & Volatility

ProKidney has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Summary

Innate Pharma beats ProKidney on 6 of the 10 factors compared between the two stocks.

About ProKidney

(Get Free Report)

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

About Innate Pharma

(Get Free Report)

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.